Welcome to our dedicated page for Elutia news (Ticker: AZYO), a resource for investors and traders seeking the latest updates and insights on Elutia stock.
Elutia Inc. (AZYO) specializes in biologic solutions that enhance medical device compatibility, focusing on orthopedic applications and tissue remodeling technologies. This page provides essential updates on corporate developments, regulatory actions, and clinical advancements.
Key resources include official statements on product safety initiatives like the voluntary bone matrix suspension, progress reports on innovations such as the CanGaroo implant, and financial disclosures. All content is vetted from primary sources including FDA communications and company filings.
Visitors will find updates on quality control measures, partnership announcements with healthcare authorities, and executive commentary from CEO Dr. Randy Mills. Bookmark this page for real-time access to earnings reports, strategic initiatives, and material event disclosures.
For direct access to Elutia's investor materials or to review official regulatory submissions, visit the dedicated investor portal. Check back regularly for verified updates on product pipelines and corporate governance matters.
Aziyo Biologics, Inc. (Nasdaq: AZYO) reported first-quarter 2022 financial results with total net sales dropping 11% to $11.5 million. Core product sales fell to $8.1 million, while non-core product sales increased to $3.4 million. Notably, the CanGaroo and SimpliDerm products saw over 25% revenue growth. Gross profit also declined to $4.3 million, with a gross margin of 37%. The company recorded a net loss of $8.1 million, compared to $5.1 million in Q1 2021. Aziyo expects total net sales for 2022 to range between $47 and $50 million, depending on the FDA clearance of CanGaroo RM.
Aziyo Biologics, Inc. (AZYO), a company in regenerative medicine, will report its Q1 2022 earnings after the market closes on May 9, 2022. The management will conduct a conference call at 4:30 PM ET on the same day to discuss financial performance. This call will also be available via webcast on the company’s website. Established in 2015, Aziyo focuses on innovative products for surgical patients, particularly those with implantable medical devices, and operates in cardiovascular, orthopedic, and reconstructive sectors.
Aziyo Biologics (Nasdaq: AZYO) will highlight its CanGaroo Envelope during a Key Opinion Leader (KOL) Call hosted by Cowen on April 18, 2022. The CanGaroo Envelope supports cardiac implantable electronic devices, enhancing healing through its extracellular matrix composition. Featured KOLs include Dr. Benjamin D’Souza and Dr. Simon Okewole. The Company has recently submitted a 510(k) application for the CanGaroo RM, which includes antibiotics, and it is currently under FDA review.
Aziyo Biologics, Inc. (Nasdaq: AZYO) has filed a 510(k) premarket notification with the FDA for its CanGaroo RM Antibacterial Envelope, a next-generation biomaterial designed for implantable electronic devices. This new version incorporates antibiotics Rifampin and Minocycline to reduce bacterial colonization risks. Dr. Benjamin D’Souza emphasized its potential benefits for patients undergoing cardiac device implants. CEO Ron Lloyd highlighted this submission as a major step towards improving patient outcomes in surgeries involving electronic devices.
Aziyo Biologics (Nasdaq: AZYO) announced its participation in the Lytham Partners Spring 2022 Investor Conference, occurring virtually from April 4-7, 2022. The company will present via webcast at 11:00 AM ET on April 4, with the presentation available for replay on its website. Management will also engage in one-on-one meetings during the event. Aziyo focuses on regenerative medicine, developing differentiated products to enhance surgical outcomes, particularly for patients using implantable medical devices. Founded in 2015, the company offers products in cardiovascular, orthopedic, and reconstructive fields.
Aziyo Biologics, Inc. (Nasdaq: AZYO) reported a net sales decrease of 13% to $10.9 million in Q4 2021, compared to $12.5 million in Q4 2020. However, excluding discontinued FiberCel sales, revenue increased by 6%. For the full year 2021, net sales rose 11% to $47.4 million, with core products sales growing 3.8%. The company completed a PIPE financing generating $13.8 million, enhancing cash reserves to $30.4 million. Aziyo maintains its 2022 sales guidance of $47 to $50 million, anticipating a breakout year with the introduction of CanGaroo RM, pending FDA clearance.
Aziyo Biologics, a regenerative medicine company listed on Nasdaq as AZYO, announced its participation in the 42nd Annual Cowen Health Care Conference on March 9, 2022. The event will feature a fireside chat scheduled for 12:50 p.m. ET, along with one-on-one meetings. A live and archived webcast will be accessible through the Investors section of the company’s website. Founded in 2015, Aziyo Biologics specializes in innovative products aimed at enhancing surgical outcomes, particularly for patients receiving implantable medical devices.
Aziyo Biologics (Nasdaq: AZYO) is set to announce its fourth quarter and full year 2021 earnings results on March 3, 2022, after the market closes. The management will discuss financial performance during a conference call at 4:30 p.m. ET. This will be available via webcast on the company’s website. Aziyo focuses on regenerative medicine, developing products for surgical outcomes, particularly in cardiovascular and orthopedic specialties, since its inception in 2015.
Aziyo Biologics, Inc. (Nasdaq: AZYO), a regenerative medicine company, will present at the H.C. Wainwright Bioconnect Virtual Conference. The pre-recorded presentation is set for January 10th at 7:00 am ET, accessible via the company’s website. Established in 2015, Aziyo focuses on innovative products to enhance surgical outcomes, particularly for patients with implantable medical devices. Their extensive portfolio includes commercial-stage offerings across cardiovascular, orthopedic, and reconstructive specialties.
Aziyo Biologics announced the completion of a private investment in public equity (PIPE) financing, raising approximately $14 million. The financing was led by Birchview Capital and included existing investors like Deerfield Management and HighCape Capital. The funds will support scaling commercial operations, generating clinical data, and development costs for the upcoming CanGaroo RM product. The investment involved purchasing 2,122,637 shares of Class A common stock and 1,179,244 shares of Class B common stock at $4.24 per share. This transaction is part of a private placement under Regulation D.
FAQ
What is the market cap of Elutia (AZYO)?
